Orchestra BioMed Inc. (OBIO)
NASDAQ: OBIO
· Real-Time Price · USD
3.02
0.04 (1.34%)
At close: Jun 27, 2025, 12:34 PM
1.34% (1D)
| Bid | 2.98 |
| Market Cap | 115.67M |
| Revenue (ttm) | 2.89M |
| Net Income (ttm) | -66.32M |
| EPS (ttm) | -1.58 |
| PE Ratio (ttm) | -1.91 |
| Forward PE | -1.75 |
| Analyst | Buy |
| Ask | 3.03 |
| Volume | 76,726 |
| Avg. Volume (20D) | 436,429 |
| Open | 2.98 |
| Previous Close | 2.98 |
| Day's Range | 2.98 - 3.08 |
| 52-Week Range | 2.37 - 8.87 |
| Beta | 0.63 |
About OBIO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol OBIO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for OBIO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Orchestra BioMed Inc. is scheduled to release its earnings on Aug 11, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+10.94%
Orchestra BioMed shares are trading higher after t...
Unlock content with
Pro Subscription
2 months ago
+0.7%
Orchestra BioMed shares are trading higher after the company announced it secured FDA Breakthrough Device Designation for AVIM therapy.
4 weeks ago · seekingalpha.com
Orchestra BioMed: Two Best-In-Class Devices And Promising PartnershipsOrchestra BioMed holds two best-in-class medical device therapies targeting large markets, with strong partnerships and equity investments from Medtronic and Terumo. Both AVIM Therapy and Virtue SAB h...
